Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. - Wikidata - awgldk - TriplyDB

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

http://www.wikidata.org/entity/Q33939971

about

18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)The clinical use of structural MRI in Alzheimer disease Toward precision medicine in Alzheimer's disease Docosahexaenoic Acid and Cognition throughout the Lifespan Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns Imago Mundi, Imago AD, Imago ADNI The Alzheimer's disease neuroimaging initiative: progress report and future plans Reduced hippocampal activity during encoding in cognitively normal adults carrying the APOE ɛ4 allele.Neuronuclear imaging in the evaluation of dementia and mild decline in cognition.Imaging endpoints for clinical trials in Alzheimer's disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Brain imaging of neurovascular dysfunction in Alzheimer's disease.Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.Oxidative stress and mitochondrial dysfunction in Alzheimer's disease.Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.Estrogen: a master regulator of bioenergetic systems in the brain and body Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.Biomarkers in Alzheimer's disease: past, present and future.Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.A review of functional brain imaging correlates of successful cognitive aging.The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.Integrating ADNI results into Alzheimer's disease drug development programs.Boosting power for clinical trials using classifiers based on multiple biomarkers.Comparing predictors of conversion and decline in mild cognitive impairment.Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

P2860

Q24186399-26B7B9CE-6E53-4B09-8BF0-436A71C5F81D Q24609648-0B805E0D-59C0-4790-A5CD-3DA4BC3561C4 Q26748939-D65F8ECC-D4A2-400D-9EA6-9A785C2441E2 Q26768442-262DDC8A-9A5A-4789-8591-B83C58D565ED Q26801629-0E685361-100A-4F57-981B-E701AE1E191A Q26825442-E60D6A2C-FE12-401F-98A3-CF353F063796 Q27006831-FB1019D3-3FC8-496E-AA37-BA01F8F22385 Q27009411-6FCCD44B-B2E1-4C0D-94B5-170D11E84009 Q28086879-9272A736-3C8C-4255-9D68-78B38CB6A97A Q28602247-6BFE5088-9BE4-4255-A812-A1E2C77007E3 Q28650395-29CB16B5-5986-49A5-992D-2C60B9AB01E6 Q28749585-8FE98BC2-F537-4002-8470-1CFD8E8555DE Q30502517-AB616050-7A3C-4C6A-9390-F60719D96E47 Q30571571-4FE83335-2B26-4DB2-9475-C4458C122891 Q30885979-277BE26B-14AD-44F2-9EE9-C45238EFF2AD Q30971403-4DF1C732-8E74-403E-954F-7E8F1248C0F1 Q31066988-78D08D52-EF9F-45F4-9295-0D1E02223803 Q31096423-31808314-DC21-4D81-B8E4-989C1D28DB28 Q33555956-DB864B5F-8CEE-45F8-ADA4-E713EBBF446F Q33573761-DF2B3FF8-6C01-4153-8ADD-E3B599326EF5 Q33623924-D8CF765F-61DA-46E1-A724-5DCCA58FBF9F Q33695122-7006C5D3-0C14-4FBC-8DBD-A79D141248DB Q33740879-C438A757-EA02-429D-98B9-66FD7D467C44 Q33758587-6CC04FB0-41C6-489A-9E35-097DA6C7B6DD Q33791646-7AC2FE03-77B7-4154-88B9-4AF6437653CB Q33798435-80665096-4F83-45A5-9430-DCA9BCE45E15 Q33816135-956FFA29-9DAE-491F-8BB0-2F280671D545 Q33819052-940375E8-FC63-489B-A49E-7E58F9C36D44 Q33842492-402D944B-316F-43F9-8D46-F5284B86F205 Q33857034-8EA1397E-7D46-480E-8669-CD4C5FD0954D Q33872248-13B45BF1-4EB0-437A-8C7A-1A77EF0A0E82 Q33920450-DB14EAEE-7CE5-4A59-83BC-BAF1AF5F4F80 Q33953180-520B96C9-DCB4-4DE5-BA61-A6D6A6BEA410 Q33987409-0C427C35-1BAE-4D6B-9E62-F27C84E8F43E Q33990250-028BA0E0-96C1-4B8B-A782-CC0D40446EA5 Q34003436-294E7C1D-84D9-4746-94FE-3CB62C687FA1 Q34047125-DC1AD4DC-B102-4E98-A574-74CB8A5B4853 Q34053358-077A2BB5-957D-406B-ADF9-662073182C45 Q34061794-E57BEC19-60E5-4BB5-B0F9-1C4A8EDE2E6A Q34065449-7B835439-9A22-4CA9-9C63-54FC5C1735B4

P2860

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

http://www.wikidata.org/entity/Q33939971

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Associations between cognitive ...... ures of decline in AD and MCI.

@ast

Associations between cognitive ...... ures of decline in AD and MCI.

@en

type

label

Associations between cognitive ...... ures of decline in AD and MCI.

@ast

Associations between cognitive ...... ures of decline in AD and MCI.

@en

prefLabel

Associations between cognitive ...... ures of decline in AD and MCI.

@ast

Associations between cognitive ...... ures of decline in AD and MCI.

@en

P1433

Q33939971-84972D9B-E752-40FA-AF53-4B68BD1AF047

P1476

Q33939971-D0D11F79-0506-4E98-B057-7853C0519116

P2093

Q33939971-57ECDE7F-534A-4014-898C-85CD9A54B63D

Q33939971-59F4B9E9-2EDA-4B6C-8374-B5F6BDBF2ADB

Q33939971-6555CA67-D4A8-41DB-9C88-2A50853426C5

Q33939971-91DB0AD1-6117-4418-9E07-DB29DB2DBB0A

Q33939971-921D5DF9-BC4B-4BF9-82C9-D34B6A07F650

Q33939971-F90C0B27-29E0-4F4B-923D-3BC8B6739B24

P2860

Q33939971-08145996-686D-49C0-AE84-CEED35F5EFE9

Q33939971-085923A2-9BBE-4D71-91EB-5351A9DDFE3D

Q33939971-1EFA8092-E6F8-43C9-B40E-BAED628D7AE5

Q33939971-218648AE-77AD-401B-97FE-40D5C7A25A43

Q33939971-22A71134-A616-44BC-9715-C6F980FF5B74

Q33939971-2A742ABB-9B6D-43DE-B4BA-C47BBD0E569E

Q33939971-34C653CF-5398-4245-94DD-7D2B5221B958

Q33939971-360794D5-6A9F-4107-9DA2-D66A0F85C856

Q33939971-3850B509-E58F-48EC-BF7D-D0B3CD7A39DD

Q33939971-395B0BC9-6166-436A-8025-9020A0EF1B4F

P304

Q33939971-54A39A26-F105-47B7-892A-EB2154FDC3F0

P31

Q33939971-F9232FC1-D772-4947-B342-F70745C3F8C1

P356

Q33939971-326C2A52-96F5-4DE0-A626-2E29E66F64DC

P433

Q33939971-1BC07A96-90CE-438F-B570-2D0B2EF0563A

P478

Q33939971-DACA81BD-0C48-4484-9172-EBF87AC83050

P50

Q33939971-A11D326C-8EAD-4549-B1E6-AF894DB9E9AB

Q33939971-A19FBFD6-A943-4E38-BB16-A8A06A4E1F80

Q33939971-F882B800-8C3A-4B6E-9C52-C2C44E38498A

P577

Q33939971-5A89EFAE-BC0B-4F4C-802E-8CAA87D09929

P5875

Q33939971-76E77E9F-6FFB-456D-82A9-CA4F200AB1FA

P698

Q33939971-F19B6E29-AD9A-4820-B6CC-8E296CEDC470

P932

Q33939971-7B482ADA-392D-4687-82BA-76AFC419925C

P356

J.NEUROBIOLAGING.2009.07.002

P1433

Neurobiology of Aging

P1476

Associations between cognitive ...... ures of decline in AD and MCI.

@en

P2093

Cindee M Madison

http://www.w3.org/2001/XMLSchema#string

Danielle Harvey

http://www.w3.org/2001/XMLSchema#string

Norman L Foster

http://www.w3.org/2001/XMLSchema#string

Robert A Koeppe

http://www.w3.org/2001/XMLSchema#string

Susan M Landau

http://www.w3.org/2001/XMLSchema#string

William J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Random-effects models for longitudinal data

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment

Unified segmentation

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease.

Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Longitudinal volumetric MRI change and rate of cognitive decline.

P304

1207-1218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROBIOLAGING.2009.07.002

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner

P577

2009-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26722860

http://www.w3.org/2001/XMLSchema#string

P698

19660834

http://www.w3.org/2001/XMLSchema#string

P932

2891865

http://www.w3.org/2001/XMLSchema#string